Regeneron's blockbuster eye drug posts weaker sales due to inventory impact

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 02, 2024 at 11:43: AM
via U.S. drugmaker Regeneron Pharmaceuticals Inc (REGN.O) missed Wall Street estimates for quarterly profit on Thursday, hurt by softer sales of its blockbuster eye drug Eylea due to reduction in wholesaler inventory.

article source
 

<



Similar threads

cafead
Regeneron joins Koneksa Parkinson&#039;s digital biomarker study
Replies
0
Views
11
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA declines to approve Regeneron&#039;s blood cancer therapy
Replies
0
Views
30
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sanofi and Regeneron&#039;s Dupixent scores in Europe as the first biologic to treat COPD
Replies
0
Views
70
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AbbVie&#039;s Rinvoq conquers Regeneron and Sanofi&#039;s Dupixent in eczema trial—again
Replies
0
Views
144
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA blocks approval of Regeneron&#039;s blood cancer drug over confirmatory trial enrollment
Replies
0
Views
73
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote